IQVIA
IQV · NYSE · USD · Healthcare
1What is happening
IQVIA has fallen 4% since its 6-week high on 27/10/2026. How it continues – phase and signs – you see with a free account.
Free account · 3 stocks and coins a dayfrom the 6-week high-4.5%
Other view · 18 analystsHorizon: 12 months18 Buy · 2 Hold · 0 Sell2Our assessment
No dip56How it continues – phase and signs – you see with a free account.
3Your next step
Marking places no order – it only helps you keep track.
More details · reasons, figures, alerts
How deep is the dip?
- from the 6-week high-4.5%
Highest daily price: $284.50 on 27/10/2026 · reference of the assessment · also the highest of the last 3 months
- from the 52-week high-4.5%
Highest price in 52 weeks: $284.50 (Yahoo)
What analysts expect
Most of the 18 analysts say buy. They look about 12 months ahead – DipCatcher only 14 trading days.
- Buy
- 1890 %
- Hold
- 210 %
- Sell
- 00 %
Average price target$311.89
$268.00 to $346.00 · today $271.83
$268.00Ø $311.89$346.00
What is a price target?
The price an analyst expects in about 12 months. Estimates are often far apart and change frequently.
Third-party opinion, not an assessment by DipCatcher. Source: public analyst estimates, as of 08/11/2026. Not financial advice.
The company in figures
- Market value
- 44.8 bn $
- All shares together at the current price.
- P/E
- 33.1
- Price divided by earnings per share, last 12 months.
- 52-week range
- $154.50 – $284.50
- Lowest and highest price of the last year.
Catalysts
42 h ago- News, last 10 days
- no recent news
- Next earnings
- —
- Last report
- 27/10/2026 +2.0% vs estimate
Key figures
- Market value
- 44.8 bn $Large cap
- P/E
- 33.1
- Volume today
- 1.0 × Øabout usual
- Beta
- 1.17swings about like the market
- 52-week range
- $154.50 – $284.50price at 90 % of the range
About IQVIA
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
- Headquarters:
- Durham, United States
- 52-week range:
- $154.50 – $284.50
- Website:
- iqvia.com
Trade levels
Why the engine says so
History for this stock or coin
Watch and alert
See which stocks they are
The engine is watching these dips right now. A free account shows the names and opens 3 full analyses a day.
- 3 full analyses a dayWith entry, target, stop and the reasons behind them.
- WatchlistFollow the stocks you care about.
Free, no payment details.
Signals are generated automatically from price, volume and technical indicators. They are not investment advice.← Back to search
Not investment advice. Investing carries risk up to total loss.